Illumina (ILMN) Stock Forecast & Price Target

Illumina is supported by a strengthening clinical franchise, where sequencing consumables now represent 65%+ of sequencing consumables revenue and clinical sales have accelerated to 20% year over year ex-China in each of the past two quarters. Its moat is reinforced by regulatory switching costs, low penetration in oncology and screening applications, and a leading cost basis that allows it to defend margins while expanding with major customers such as Natera, Guardant Health, Tempus, Caris, and GRAIL. Incremental upside also comes from BioInsight, launched in 2025, which could monetize large-scale sequencing data through licensing and subscription models, while new products are expected to add 1-2 points of growth in 2027.

Illumina is facing a negative fundamental setup because its recent clinical growth acceleration to 17% to 20% may not be durable, and even where end-market demand improves, customer-led deflation in per-sample economics limits the supplier benefit. Weak academic demand, muted research and pharma spending, and lower switching costs are pressuring sequencing consumables and overall core revenue, while the NovaSeq 6000 to NovaSeq X mix shift continues to weigh on margins. China remains a meaningful risk as sales there are expected to be about 5% of 2026 revenue, down from 10% a few years ago, and intensifying competition from Roche, MGI, private players, and long-read platforms threatens share.